HOPKINTON, Mass., April 4, 2011 /PRNewswire/ — Caliper Life
Sciences, Inc. (NASDAQ:
CALP), a leading provider of tools and services for drug
discovery, life sciences research and molecular diagnostics, today
announced the launch of XenoLight(TM) RediJect(TM) COX-2 Probe
(Fluorocoxibs), a novel fluorescent imaging agent for pre-clinical
research that specifically detects the cyclooxygenase-2 (COX-2)
biomarker noninvasively in live animal models as well as in ex vivo
tissue analysis applications. The COX-2 fluorescent probe
technology was invented at the research laboratory of Dr. Lawrence
Marnett at Vanderbilt University and is licensed to Caliper.
“COX-2 is over-expressed in a variety of inflammatory and
neoplastic diseases. The opportunity to non-invasively image
COX-2 offers promise for both the early detection of disease and
monitoring therapeutic response. The fluorocoxib probe should
be valuable to investigators in multiple disciplines, including
cancer research,” said Professor Andrew Dannenberg, Director of
Cancer Center at Weill Cornell Medical College, a research leader
in the field of COX-2 in oncology and inflammation.
Researchers can gain an understanding of therapeutic efficacy in
specific patient populations by monitoring key biomarker response
to a drug treatment. These findings then help tailor
patient-specific therapeutic strategies to improve outcomes and
advance the scope of personalized medicine. For example,
COX-2 detection in tumors has become an important tool in
predicting the outcome of various chemotherapy treatments,
including advanced lung cancer. Caliper’s RediJect COX-2
probe provides the ability to non-invasively detect COX-2 in
early-stage cancer cells, with a level of sensitivity and accuracy
not attainable by conventional methods.
“Personalized therapies to treat specific patient
population
‘/>”/>
SOURCE